Welcome to our dedicated page for Victory Square news (Ticker: VSQTF), a resource for investors and traders seeking the latest updates and insights on Victory Square stock.
Victory Square Technologies Inc. (VSQTF) generates frequent news as a venture builder with a diversified portfolio of early-stage technology companies. Company updates often combine financial results with detailed commentary on portfolio performance, particularly in digital health, artificial intelligence, Web3, gaming, climate tech, and pet wellness.
News releases commonly cover quarterly and annual financial results, including adjusted revenue, GAAP revenue, gross margin, and adjusted EBITDA, along with management’s discussion of portfolio momentum and capital allocation. Investors can read about developments such as revenue growth, profitability trends, and the impact of monetizing specific assets.
Another major theme in Victory Square’s news flow is portfolio company progress. Regular updates highlight Hydreight Technologies’ expansion as a digital health platform, the evolution of the VSDHOne infrastructure, Insu Therapeutics’ work on oral insulin delivery, Pawsible Ventures’ pet health initiatives, XR Immersive Tech’s move into health-related IP, and SafeTest’s digital health activities in Brazil. The company also reports on transactions involving holdings like BlockX and performance milestones at GameOn.
Corporate actions and strategic initiatives are also featured. Victory Square has announced a Normal Course Issuer Bid to repurchase shares, described a $10 million digital health and longevity accelerator, and provided NAV-focused corporate updates and investor webinar details. For investors tracking VSQTF, this news page offers a consolidated view of how Victory Square’s portfolio and strategy evolve over time, including financial metrics, sector-specific developments, and capital recycling decisions.
Victory Square Technologies announced that its portfolio company, Hydreight Technologies, has added Tirzepatide to its weight loss portfolio. Tirzepatide, an FDA-approved medication for type 2 diabetes, is also effective for weight loss and will be available through Hydreight's platform across 700 cities in the US. This addition complements their existing GLP-1 injections, including Semaglutide, which saw a 250% increase in orders between January and February 2024. Hydreight's growing network includes over 3,000 nurses and 107 white-label locations. In 2023, Hydreight reported a 102% revenue increase, reaching $17.05 million. This expansion aligns with the projected growth in the anti-obesity market, which could reach $100 billion by 2030.
Victory Square Technologies reported revenue growth from $5.9M in 2022 to $12M in 2023, with a gross margin increase to $5.49M. Cash and liquid securities stand at $4.9M. Key portfolio updates include Hydreight’s 102% revenue growth, GameOn’s $9.3M deal with Sportsology, and XR Immersive’s expansion with over 500 VR operators. Covalent’s market cap rose 28% QoQ, while FansUnite generated $23.72M in revenue for 2023. Notable transactions include Turnium’s LOI to acquire Claratti and Stardust Solar’s acquisition proposal by BOLD TSX.V valued at $15.4M. Victory Square will host an investor webinar on May 23, 2024.
Victory Square Technologies reported its 2023 financial results, showcasing a diverse portfolio of 25+ innovative companies in sectors like Digital Health, AI, ML, Blockchain, VR/AR, Gaming, and Climate Tech. With revenue reaching $12,055,070, a significant increase from the previous year, the company also holds cash & liquid securities of approximately $4,903,363. Victory Square's business model focuses on buying, building, and investing in early-stage tech companies, with substantial involvement from its management team and advisors. The company aims to drive value by monetizing investments and reinvesting gains in new innovations. Despite a net loss primarily due to fair value write-downs on portfolio investments and operating losses, Victory Square remains optimistic about its continued growth in 2024.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.